HC Wainwright & Co. analyst Edward White downgrades Vyant Bio (NASDAQ:VYNT) from Buy to Neutral.
Lantheus And POINT Biopharma Announce Strategic Collaboration And Exclusive License Agreements For The Commercialization Of PNT2002 & PNT2003
Lantheus Holdings, Inc. (”Lantheus”) (NASDAQ:LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to
